Samsung BioLogics is reported to be ready to file an IPO application this week in South Korea that is seen raising more than $2 billion.
Pfizer executives spent considerable time on the second-quarter earnings call discussing biosimilar plans related to China and South Korea's Celltrion.
Gilead Sciences has confirmed a report that several Indian drugmakers have licenses to manufacture its cutting-edge hepatitis treatment Epclusa.
China's Shanghai Fosun wins race for India's Gland
China's Shanghai Fosun Pharmaceuticals has reportedly won a bidding war for India's privately held injectable maker Gland Pharma in a rare cross-…
Exceptions on 15 ingredients from a banned plant run by China's Zhejiang Hisun Pharmaceuticals have raised questions on the ability of inspectors to…
South Africa's Aspen Pharmacare has set its sights on rapid expansion in China.
A dispute over the pricing of drugs in Pakistan that has led many of the pharmaceutical manufacturers in the country to stop making tuberculosis drugs is…
Indian firms Sun Pharmaceutical Industries, Aurobindo Pharma and Glenmark Pharmaceuticals are in the catbird seat on generics of AstraZeneca's Crestor.
Zhejiang Hisun Pharmaceuticals has won China license rights to epithelial mAb oncology early-stage candidate pritumumab from Nascent Biotech.